 | | Vol. 13.42 – 26 October, 2021 |
| |
|
|
| The authors showed that skeletal muscle of type 2 diabetes mellitus patients exhibited degenerative remodeling of the ECM that was associated with a selective increase of a subpopulation of fibro-adipogenic progenitors (FAPs) marked by expression of THY1 (CD90)—the FAPCD90+.
[Cell Metabolism] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| In vitro results showed that MSC-small extracellular vesicles reduced senescent biomarkers, decreased senescence-associated secretory phenotype, rescued angiogenesis, migration and other dysfunctions in senescent endothelial cell induced by oxidative stress.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Inspired by the natural incubation mechanism of roe, investigators presented immune-isolating, wet-adhesive, and nutrient-rich microcapsules for therapeutic MSCs encapsulation.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers examined MSCs/Cutibacterium acnes interaction and analyzed the subsequent MSCs and bacteria’s behaviors. Infected MSCs increased the secretion of prostaglandin E2 and indolamine 2,3 dioxygenase immunomodulatory mediators.
[Acta Biomaterialia] |
|
|
|
| Investigators showed that store-dependent Ca2+ entry was essential for modulating the function of bone marrow-derived MSCs.
[NPJ Regenerative Medicine] |
|
|
|
| The authors provided a platform for identifying markers for predicting MSC functional capacity using partial least squares regression modeling that could be used as release criteria and guide future manufacturing strategies for mesenchymal stromal cells and other cell therapies.
[Cytotherapy] |
|
|
|
| TRIM14 promoted the proliferation of acute myeloid leukemia cells via activating PI3K/AKT pathway, which was reversed by human MSC-derived exosomes through delivering miR-23b-5p.
[Molecular Medicine] |
|
|
|
| Scientists developed a cell- and growth factor-free approach to induce bone formation in a critical-size bone defect by using an interconnected porous beta-tricalcium phosphate scaffold with multiple channels.
[Scientific Reports] |
| |
|
|
| MSC infusion reduced the levels of C-reactive protein, proinflammatory cytokines, and neutrophil extracellular traps, and promoted the maintenance of SARS-CoV-2-specific antibodies.
[Cell Research] |
|
|
|
| By exome sequencing of in vitro expanded mesenchymal stromal cells (MSCs) from 98 patients with myelodysplastic syndrome (MDS) and 28 healthy controls, researchers showed that these cells accumulated recurrent mutations in genes such as ZFX, RANK, and others.
[Nature Communications] |
|
|
|
| The authors revealed that MSC-derived exosomes resided specifically in the injured kidney and delivered miRNA-34c-5p to reduce cellular activation and renal interstitial fibrosis by inhibiting core fucosylation.
[Molecular Therapy] |
|
|
|
| Scientists demonstrated that MSCs derived from oral squamous cell carcinoma (OSCC) promoted the metastasis of OSCC cells by transwell assay and animal models through epithelial to mesenchymal transition.
[Cell Death Discovery] |
|
|
|
| Researchers reported two new cases of low-grade endometrial stromal sarcoma-like sarcoma in male patients, one presenting as a periprostatic/peri-rectal mass with a JAZF1-GLI3 fusion, while the other as a paratesticular mass with a JAZF1-PHF1 fusion.
[Genes Chromosomes & Cancer] |
|
|
|
|
| The authors emphasize the diverse functions of Piezo1 and Piezo2 and related signaling pathways in osteoblast lineage cells and chondrocytes, and summarize key findings about PIEZO gene mutations in human diseases.
[Bone Research] |
|
|
|
| DPP4 activity may modulate different aspects of MSC regenerative capacity. Investigators analyze the effect of different DPP4 substrates on MSCsssssss and discuss how the regulation of DPP4 activity by DPP4 inhibitor can be applied in regenerative medicine.
[Stem Cell Reviews and Reports] |
|
|
|
|
| GenFleet Therapeutics announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in a Phase Ib/II trial of GFH018 in combination with toripalimab as part of global multi-center clinical research.
[GenFleet Therapeutics] |
|
|
|
| BioCardia®, Inc. announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina.
[BioCardia®, Inc.] |
|
|
|
|
| November 8 – 16, 2021
Chicago, Ilinois, United States & Online |
|
|
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Northwestern University – Chicago, Illinois, United States |
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
| | University of Connecticut – Farmington, Connecticut, United States |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
